Vir Biotechnology, Inc. (VIR)

Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	170.08	222.95	241.58	848.63	347.82	436.58
Short-Term Investments	336.43	682.4	1,281	1,553	360.33	300.29
Cash & Short-Term Investments	506.51	905.35	1,522	2,402	708.15	736.86
Cash Growth	-44.61%	-40.53%	-36.62%	239.20%	-3.90%	92.17%
Accounts Receivable	-	-	-	-	773.08	-
Other Receivables	-	5.1	11.6	28.9	-	1.9
Receivables	-	5.1	11.6	28.9	773.08	1.9
Prepaid Expenses	36.96	42.63	40.95	57.84	73	25.61
Restricted Cash	2.22	89.39	13.27	12.68	8.59	7.99
Other Current Assets	-	-	-	17.62	-	-
Total Current Assets	545.68	1,042	1,588	2,519	1,563	772.37
Property, Plant & Equipment	121.76	122.86	167.2	188.17	130.05	79.89
Long-Term Investments	304.21	190.02	105.28	23.93	201.39	-
Goodwill	16.94	16.94	16.94	16.94	16.94	16.94
Other Intangible Assets	7.92	8.12	22.57	32.76	33.29	33.82
Other Long-Term Assets	22.94	18.42	18.86	21.23	9.78	15.75
Total Assets	1,019	1,399	1,919	2,802	1,954	918.76
Accounts Payable	6.85	5.08	6.33	6.42	6.52	5.08
Accrued Expenses	68.38	66.53	82.15	462.07	129.54	69.84
Current Portion of Leases	-	7.75	12.87	4.14	3.93	3.63
Current Income Taxes Payable	-	-	-	15.23	6.22	-
Current Unearned Revenue	-	12.65	64.85	15.52	98.21	6.45
Other Current Liabilities	-	27.65	9.2	7.65	96.83	14.07
Total Current Liabilities	75.22	119.66	175.41	511.03	341.24	99.06
Long-Term Leases	91.22	90.14	111.67	123.84	133.56	66.56
Long-Term Unearned Revenue	9.43	-	-	53.21	3.82	3.82
Long-Term Deferred Tax Liabilities	-	-	-	-	18.44	3.25
Other Long-Term Liabilities	47.49	38.63	41.74	36.05	25.36	29.22
Total Liabilities	223.36	248.43	328.82	724.13	522.42	201.91
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,953	1,912	1,829	1,710	1,572	1,385
Retained Earnings	-1,155	-759.78	-237.82	377.24	-138.6	-667.18
Comprehensive Income & Other	-1.91	-1.72	-0.82	-9.12	-1.1	-1.28
Total Common Equity	796.1	1,150	1,590	2,078	1,432	716.85
Shareholders' Equity	796.1	1,150	1,590	2,078	1,432	716.85
Total Liabilities & Equity	1,019	1,399	1,919	2,802	1,954	918.76
Total Debt	91.22	97.89	124.54	127.97	137.49	70.18
Net Cash (Debt)	415.3	807.46	1,398	2,274	570.66	666.68
Net Cash Growth	-48.20%	-42.24%	-38.53%	298.50%	-14.40%	73.98%
Net Cash Per Share	3.01	5.93	10.42	16.87	4.28	5.59
Filing Date Shares Outstanding	139.02	137.14	135.03	133.53	132.3	127.84
Total Common Shares Outstanding	139.02	136.96	134.78	133.24	131.16	127.42
Working Capital	470.46	922.8	1,413	2,008	1,222	673.3
Book Value Per Share	5.73	8.40	11.80	15.60	10.92	5.63
Tangible Book Value	771.24	1,125	1,551	2,028	1,382	666.1
Tangible Book Value Per Share	5.55	8.22	11.51	15.22	10.53	5.23
Machinery	-	44.9	49.4	41.93	22.57	18.77
Construction In Progress	-	1.07	0.23	-	26.93	1.14
Leasehold Improvements	-	53.99	80.29	84.42	7.83	7.27

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q